1-三苯甲基-1H-咪唑-4-羧酸乙酯 | 53525-60-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 1-三苯甲基-1H-咪唑-4-羧酸乙酯
• 中文别名: 1-三苯基咪唑-4-甲酸乙酯；7-氨基-4-三氟甲基香豆素
• 英文名称: ethyl 1-trityl-1H-imidazole-4-carboxylate
• 英文别名: ethyl 1-tritylimidazole-4-carboxylate
• CAS: 53525-60-3
• 化学式: C₂₅H₂₂N₂O₂
• 分子量: 382.462
• InChiKey: KXDKACKOPKUCBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于室温、干燥处，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 1-trityl-1H-imidazole-4-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 1-trityl-1H-imidazole-4-carboxylate
CAS number: 53525-60-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C25H22N2O2
Molecular weight: 382.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-三苯甲基-1H-咪唑-4-羧酸乙酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以86%的产率得到1-三苯甲基-1H-咪唑-4-甲醇
  参考文献：
  名称：

  Davis, Dwight P.; Kirk, Kenneth L.; Cohen, Louis A., Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 253 - 256

  摘要：

  DOI：
• 作为产物：
  描述：

  三苯基氯甲烷 、 咪唑-4-甲酸乙酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以97%的产率得到1-三苯甲基-1H-咪唑-4-羧酸乙酯
  参考文献：
  名称：

  结构动力学关系和分子动力学显示不可逆的二酰基甘油脂肪酶抑制剂中杂环离去基团的关键作用。

  摘要：

  共价不可逆的，基于机理的酶抑制剂的药物发现计划通常着重于通过生化测定中IC50值确定的效价优化。这些测定不允许将结合活性（Ki）和反应性（运动）表征为共价抑制剂的各个动力学参数。在这里，我们报告动力学底物测定法的发展，以研究三唑脲衍生物作为二酰基甘油脂肪酶（DAGL）-α抑制剂的杂环离去基团的酸度（pKa）的影响。令人惊讶地，我们发现抑制剂的反应性与离去基团的pKa不相关，而杂环核中氮原子的位置在很大程度上决定了抑制剂的结合活性。通过共价键合的Michaelis-Menten配合物的分子动力学模拟证实并澄清了这一发现。希望对共价丝氨酸水解酶抑制剂的结合特性有更深入的了解，有助于发现和开发更具选择性的共价抑制剂。

  DOI：

  10.1021/acs.jmedchem.9b00686

文献信息

• [EN] NAPHTHO[2,1 -D]THIAZOLE DERIVATIVES, COMPOSITIONS THEREOF AND METHODS OF TREATING DISORDERS<br/>[FR] DÉRIVÉS DE NAPHTO [2,1-D]THIAZOLE, COMPOSITIONS DE CEUX-CI ET MÉTHODES DE TRAITEMENT DE TROUBLES
  申请人：REVERIE LABS INC

  公开号：WO2021102410A1

  公开（公告）日：2021-05-27

  The present application relates to the compounds of formula (I) that inhibit CDK9, pharmaceutical compositions thereof and methods of making and using the same.

  本申请涉及抑制CDK9的化合物（I）的公式，以及其药物组合物的制备方法和使用方法。
• [EN] BENZENE SULFONAMIDES AS CCR9 INHIBITORS<br/>[FR] BENZÈNE-SULFONAMIDES À TITRE D'INHIBITEURS DE CCR9
  申请人：NORGINE BV

  公开号：WO2015097122A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

  本发明涉及作为CCR9调节剂有用的化合物，包含这些化合物的组合物，制备它们的方法，以及使用它们的方法。具体而言，本发明涉及能够通过作为部分激动剂、拮抗剂或逆激动剂来调节CCR9受体功能的化合物。这些化合物可能有助于治疗、预防或缓解与CCR9激活相关的疾病或状况，包括炎症和免疫性疾病或状况，如炎症性肠病（IBD）。
• (Substituted aralkyl) heterocyclic compounds
  申请人：Imperial Chemical Industries plc

  公开号：US04935437A1

  公开（公告）日：1990-06-19

  A (substituted-aralkyl)heterocyclic compound of the formula I ##STR1## wherein R.sup.1 is an azido, carbamoyl, cyano, formyl, hydroxy or nitro radical, a 1-6C 1-hydroxyalkyl, alkoxy, alkylcarbamoyl, alkylthio, alkylsulphinyl or alkylsulphonyl radical, a 2-cyanoethyl radical, optionally bearing one to four 1-6C alkyl substituents, or a 2-6C alkanoyl, halogenoalkanoyl, alkanoyloxy, alkanoylamino, dialkylcarbamoyl or alkoxycarbonyl radical; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, dueterioalkyl or halogenoalkyl radical, or a phenyl or phenyl(1-6C alkyl) radical, in each of which the phenyl may optionally bear one or more substituents; or R.sup.2 and R.sup.3, together with the carbon atom to which they are attached, may form a 3- to 6-membered ring; or R.sup.1 R.sup.2 R.sup.3 C- is a 1,1-dicyanoethyl or trifluoromethylsulphonyl radical; R.sup.4 is a hydrogen or halogen atom, a cyano or nitro radical or a 1-6C alkyl or halogenoalkyl radical; R.sup.5 has any of the values defined above for the group R.sup.1 R.sup.2 R.sup.3 C but is not necessarily the same as R.sup.1 R.sup.2 R.sup.3 C, or has any of the values defined above for R.sup.4 but is not necesarily the same as R.sup.4, or is a carbamoyl, 1-pyrrolidinyl-carbonyl, piperidinocarbonyl, morpholinocarbonyl or nitro radical, a 1-6C alkoxy or halogenoalkoxy radical or a 2-6C alkanoyl or alkoxy-carbonyl radical; A is a methylene or ethylene radical optionally bearing one or more substituents selected from deuterium and halogen atoms, carbamoyl, cyano and hydroxy radicals, 1-6C alkyl and alkoxy radicals, and 2-6C alkanoyloxy radicals provided that when A is linked to R.sup.6 through a nitrogen atom thereof, it may not bear a hydroxy, alkoxy or alkanoyloxy substituent on the carbon atom adjacent to such nitrogen atoms; and R.sup.6 is a 1H-1,2,4-triazol-1-yl, 4H-1,2,4-triazol-4-yl, 1H-imidazol-1-yl, 5-cyano-1H-imidazol-1-yl, 3-pyridyl or 5-pyrimidinyl radical, or a 1H-imidazol-1-yl radical, bearing at the 5-position thereof a 1-6C alkyl substituent which is itself optionally substituted by one or more carbamoyl, cyano, hydroxy or 2-6C alkoxycarbonyl radicals; and provided that when R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen, A is a methylene radical and R.sup.6 is a 3-pyridyl radical, R.sup.1 is not a cyano, hydroxy or hydroxymethyl radical, and when R.sup.1 is a hydroxy radical, R.sup.3, R.sup.4 and R.sup.5 are hydrogen, A is a methylene radical and R.sup.6 is 3-pyridyl, R.sup.2 is not a methyl or a 2-chloro-1-methylethyl radical, and provided that when R.sup.1 is a methoxycarbonyl radical, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are hydrogen and A is a methylene radical, R.sub.1 is not a 1H-imidazol-1-yl radical; and the pharmaceutically acceptable acid addition salts thereof.

  一种公式I的（替代芳基）杂环化合物 其中R.sup.1是azido、carbamoyl、cyano、formyl、羟基或硝基基团，1-6C 1-羟基烷基、烷氧基、烷基氨甲酰、烷基硫醚、烷基磺醚或烷基磺酰基团，2-氰乙基基团，可选地带有一到四个1-6C烷基取代基，或2-氰乙基基团，可选地带有一到四个1-6C烷基取代基，或2-6C烷酰基、卤代烷酰基、烷酰氧基、烷酰胺基、二烷基氨基甲酰基或烷氧羰基基团；R.sup.2和R.sup.3，可能相同也可能不同，分别是氢原子、1-6C烷基、二氘烷基或卤代烷基基团，或苯基或苯基（1-6C烷基）基团，其中苯基可能可选地带有一个或多个取代基；或R.sup.2和R.sup.3，连同它们附着的碳原子，可形成3-至6-成员环；或R.sup.1 R.sup.2 R.sup.3 C-是1,1-双氰乙基或三氟甲基磺酰基团；R.sup.4是氢或卤原子、氰基或硝基基团或1-6C烷基或卤代烷基基团；R.sup.5具有上述R.sup.1 R.sup.2 R.sup.3 C基团定义的任何值，但不一定与R.sup.1 R.sup.2 R.sup.3 C相同，或具有上述R.sup.4定义的任何值，但不一定与R.sup.4相同，或是carbamoyl、1-吡咯烷基羰基、哌啶基羰基、吗啉基羰基或硝基基团，1-6C烷氧基或卤代烷氧基基团或2-6C烷酰基或烷氧羰基团；A是一个亚甲基或乙烯基基团，可选地带有一个或多个取代基，所述取代基选自氘和卤原子、carbamoyl、氰基和羟基基团、1-6C烷基和烷氧基团，以及2-6C烷酰氧基基团，条件是当A通过其氮原子连接到R.sup.6时，不能在相邻于该氮原子的碳原子上带有羟基、烷氧基或烷酰氧基取代基；R.sup.6是1H-1,2,4-三唑-1-基、4H-1,2,4-三唑-4-基、1H-咪唑-1-基、5-氰基-1H-咪唑-1-基、3-吡啶基或5-嘧啶基基团，或1H-咪唑-1-基，其在其5-位置带有一个1-6C烷基取代基，该取代基本身可选地被一个或多个carbamoyl、氰基、羟基或2-6C烷氧羰基团取代；条件是当R.sup.2、R.sup.3、R.sup.4和R.sup.5为氢时，A是亚甲基基团，R.sup.6是3-吡啶基团，R.sup.1不是氰基、羟基或羟甲基基团，当R.sup.1为羟基基团时，R.sup.3、R.sup.4和R.sup.5为氢，A是亚甲基基团，R.sup.6是3-吡啶基团，R.sup.2不是甲基或2-氯-1-甲基乙基基团，条件是当R.sup.1为甲氧羰基基团时，R.sup.2、R.sup.3、R.sup.4和R.sup.5为氢，A是亚甲基基团，R.sub.1不是1H-咪唑-1-基；以及其药用可接受的酸盐。
• PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE
  申请人：TIANJIN WEIJIE PHARMACEUTICAL CO., LTD

  公开号：US20160272594A1

  公开（公告）日：2016-09-22

  The present invention discloses a preparation method of 2,3-dimethyl phenyl-1-trityl-imidazole-4-ketone. In accordance with this method, imidazole-4-ethyl formate is used as a raw material; ethyl formate is used for amino protection, 1-trityl-1H-imidazole-4-formic acid is obtained after basic hydrolysis; 1-trityl-1H-imidazole-4-formic acid and N,O-dimethylhydroxylamine hydrochloride are subjected to condensation so as to obtain N-methoxyl-N-methyl-1-trityl-1H-imidazole-4-formamide; and N-methoxyl-N-methyl-1-trityl-1H-imidazole-4-formamide and a Grignard reagent prepared by the reaction of 2,3-dimethylbromobenzene with magnesium are subjected to a Grignard reaction, and then the target product 2,3-dimethyl phenyl-1-trityl-1H-imidazole-4-ketone is obtained. Compared with the reported preparation methods, the preparation method is more convenient to operate and is beneficial for industrial production.

  本发明公开了2,3-二甲基苯基-1-三苯基-咪唑-4-酮的制备方法。根据该方法，咪唑-4-乙酰甲酸乙酯用作原料；乙酸乙酯用于氨基保护，碱性水解后得到1-三苯基-1H-咪唑-4-甲酸；1-三苯基-1H-咪唑-4-甲酸和N,O-二甲基羟胺盐酸盐进行缩合反应，得到N-甲氧基-N-甲基-1-三苯基-1H-咪唑-4-甲酰胺；N-甲氧基-N-甲基-1-三苯基-1H-咪唑-4-甲酰胺和由2,3-二甲基溴苯与镁反应制备的格氏试剂进行格氏反应，然后得到目标产物2,3-二甲基苯基-1-三苯基-1H-咪唑-4-酮。与已报道的制备方法相比，该制备方法操作更便捷，有利于工业生产。
• Belgodere; Bossio; Parrini, Arzneimittel-Forschung/Drug Research, 1980, vol. 30, # 7, p. 1051 - 1056
  作者：Belgodere、Bossio、Parrini、Pepino

  DOI：——

  日期：——